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Gene-based tests to study the combined effect of rare variants on a particular phenotype
have been widely developed for case-control studies, but their evolution and adaptation
for family-based studies, especially studies of complex incomplete families, has been
slower. In this study, we have performed a practical examination of all the latest
gene-based methods available for family-based study designs using both simulated and
real datasets. We examined the performance of several collapsing, variance-component,
and transmission disequilibrium tests across eight different software packages and
22 models utilizing a cohort of 285 families (N = 1,235) with late-onset Alzheimer
disease (LOAD). After a thorough examination of each of these tests, we propose a
methodological approach to identify, with high confidence, genes associated with the
tested phenotype and we provide recommendations to select the best software and
model for family-based gene-based analyses. Additionally, in our dataset, we identified
PTK2B, a GWAS candidate gene for sporadic AD, along with six novel genes (CHRD,
CLCN2, HDLBP, CPAMD8, NLRP9, and MAS1L) as candidate genes for familial LOAD.
Keywords: gene-based, family-based, clustering, variance-component, transmission disequilibrium, rare variants,
whole exome sequencing, Alzheimer’s disease

INTRODUCTION
Alzheimer disease (AD) is a complex condition for which almost 50% of its phenotypic variability
is due to genetic causes; yet only 30% of the genetic variability is explained by known markers
(Ridge et al., 2016). GWAS studies have identified more than 20 risk loci (Lambert et al., 2013) and
sequencing studies have identified additional genes harboring low frequency variants with large
effect size (TREM2, PDL3, UNC5C, SORL1, and ABCA7; Sims et al., 2017). Recent studies also
indicate that Late-Onset AD (LOAD) families are enriched for genetic risk factors (Cruchaga et al.,
2017). Therefore, studying those families may lead to the identification of novel variants and genes
(Guerreiro et al., 2013; Cruchaga et al., 2014).
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et al., 2001; Ott et al., 2011; De et al., 2013; Ionita-Laza et al.,
2013). TDT works under the paradigm of Mendel’s laws to
determine which marker in the affected offspring is responsible
for the phenotype (Zöllner et al., 2004). TDT methods have been
extended to test rare-variants by grouping information across
multiple variants within a genomic region (He et al., 2014).
However, these methods were still not valid for incomplete or
nuclear families that have several affected offspring. Considering
the late-onset nature of Alzheimer disease it is often difficult
to obtain genetic information from parents (to conform trios)
or nuclear family units. The typical pedigree in familial LOAD
represents incomplete, large familial units (Figure 1). Most of
the early software for gene-based family-based studies were not
suitable for complex pedigrees like those observed in Alzheimer
studies. In recent years gene-based methods, whether referring to
collapsing, variance-component, or transmission disequilibrium
tests, have been adapted to account for complex family structure
in its gene-based calculations. Among the software that can
manage large pedigrees we find SKAT (Wu et al., 2011), FSKAT
(Yan et al., 2015), GSKAT (Wang et al., 2013), RV-GDT (He et al.,
2017), EPACTS (http://genome.sph.umich.edu/wiki/EPACTS),
FarVAT (Choi et al., 2014), PedGene (Schaid et al., 2013), and
RareIBD (Sul et al., 2016).
In this study, we wanted to evaluate the performance of the
eight most common gene-based family-based methods available
by using a real dataset, over 250 multiplex families affected with
Alzheimer disease, under different conditions and models. We
simulated multiple scenarios in which candidate variants in the
same gene perfectly segregates with disease status to rank the
different programs and models. We also tested the performance
of these tests for identifying known causal genes for AD in our
cohort. Finally, we performed genome-wide analyses to evaluate
the power of each of these tests. Altogether, we discuss the pros
and cons of each method that can be informative for other
investigators performing similar analyses: complex diseases in
complex, incomplete, large families. We want to emphasize that
although this work focused on AD, the information extracted
from this work can be applied to other complex traits as well.
Finally, based on the results from the methods analyzed, we
present some candidate genes for AD.

Current consensus is that the missing heritability for complex
traits like AD may be hidden within rare variants that have low
to moderate effect on disease risk (Frazer et al., 2009; Manolio
et al., 2009; Cirulli and Goldstein, 2010). The rarity of these
markers requires specific study designs and statistical analyses
for their detection. The simplest approach to detect rare variants
for association is to test each variant individually using standard
contingency table and regression methods. But due to the limited
number of observations of the rare minor allele for a specific
variant, the statistical power to detect association with any rare
variant is limited; hence, extremely large samples are required
and a more stringent multiple-test correction is necessary (Li
and Leal, 2008; Bansal et al., 2010). It has been acknowledged
that the best alternative to single-variant analysis is to collapse
sets of pre-defined candidate rare variants within significant
units, usually genes (gene-based sets) (Neale and Sham, 2004;
Lee et al., 2014). For collapsing tests each variant is given a
certain weight and the weights of all variants within the region
are summed; depending on the weights and how summation is
performed there are three major types of gene-based methods:
collapsing tests, variance-component tests, and combined tests
(Lee et al., 2014). Collapsing tests analyze whether the overall
burden of rare variants is significantly different between cases
and controls by regressing disease status on minor allele counts
(MAC). The Cohort Allelic Sum Test (CAST) is a dominant
genetic model which assumes that the presence of any rare variant
increases disease risk (Morgenthaler and Thilly, 2007); whereas
the Combined Multivariate and Collapsing (CMC) method
collapses rare variants in different MAF categories and evaluates
the joint effect of common and rare variants through Hoteling’s
test (Li and Leal, 2008). However, neither CAST nor CMC tests
account for directional effect. The Variable Threshold (VT) test
does allow for both trait-increasing and trait-decreasing variants;
it selects optimal frequency thresholds for burden tests of rare
variants and estimates p-values analytically or by permutation
(Price et al., 2010). Variance-componence methods test for
association by evaluating the distribution of genetic effects for a
group of variants while appropriately weighting the contribution
of each variant. The sequence kernel association test (SKAT)
casts the problem to mixed models (Lee et al., 2014) and, in
the absence of covariates, SKAT reduces to a C-alpha test (Neale
et al., 2011). Finally, collapsing and variance component tests can
be combined into one statistical method, the SKAT-O approach
(Lee et al., 2012), which is statistically efficient regardless of the
direction and effect of the variants tested.
All these methods were initially designed for unrelated casecontrol studies; but considering the rarity of these variants,
large datasets are required to achieve statistical power (Laird
and Lange, 2006). Alternatively, family-based studies in which
several family members share the same phenotype may provide
more statistical power than regular case-controls studies (Li
et al., 2006; Cirulli and Goldstein, 2010; Kazma and Bailey,
2011; Ott et al., 2011). Pioneering methods for gene-based
analyses in familial datasets are based on the transmission
disequilibrium test (TDT–Spielman et al., 1993) which uses
the marker genotype of an affected child and genotypes of
the parents to test for association (Laird et al., 2000; Horvath
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MATERIALS AND METHODS
Cohort
The LOAD families included in this study originated from two
cohorts: Washington University School of Medicine (WUSM;
n = 1,144) and Alzheimer Disease Sequencing Project (ADSP;
n = 91) (Table 1).

WUSM Cohort
Samples from the Washington University School of Medicine
(WUSM) cohort were recruited by either the Charles F. and
Joanne Knight Alzheimer’s Disease Research Center (Knight
ADRC) at the WUSM in Saint Louis or the National Institute
on Aging Genetics Initiative for Late-Onset Alzheimer’s Disease
(NIA-LOAD). This study was approved by each recruiting
center’s Institutional Review Board and research was carried out
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FIGURE 1 | Structure of families used in this study. Black diamonds represent cases and white diamonds represent controls. Y: genetic data available. N: no genetic
data available.
TABLE 1 | Demographic data for the familial dataset employed in this study.
N

*Age ± SD

*Age range

% Fe

% APOE4

Cases

824

73 ±7

48–99

63

73

Controls

411

83 ± 9

39–104

59

51

Total

1235

77 ± 10

39–104

61

65

to increased risk for LOAD (https://www.niagads.org/adsp/
content/home). During the discovery phase, ADSP generated
whole genome sequence (WGS) data from members of multiplex
LOAD families, and whole exome sequence (WES) data
from a large case-control cohort. These data are available to
qualified researchers through the database of Genotypes and
Phenotypes (https://www.ncbi.nlm.nih.gov/gap Study Accession:
phs000572.v7.p4).
The familial cohort of the ADSP consists of 582 individuals
from 111 multiplex AD families from European-American,
Caribbean Hispanic, and Dutch ancestry (details about the
samples are available at NIAGADS). We downloaded raw data
(.sra format) from dbGAP for 143 IDs (113 cases and 23 controls)
from 37 multiplex families of European-American ancestry that
were incorporated with the WUSM cohort.

*Age At Onset (AAO) for cases and Age at Last Assessment (ALA) for controls.

in accordance with the approved protocol. Written informed
consent was obtained from participants and their family
members by the Clinical and Genetics Core of the Knight ADRC.
The approval number for the Knight ADRC Genetics Core family
studies is 201104178. The NIA-LOAD Family Study has recruited
multiplex families with two or more siblings diagnosed with
LOAD across the United States. A description of these samples
has been reported previously (Wijsman et al., 2011; Cruchaga
et al., 2012; Fernández et al., 2017). We selected individuals for
sequencing from families in which APOEε4 did not segregate
with disease status, and in which the proband of the family did
not carry any known mutation in APP, PSEN1, PSEN2, MAPT,
GRN, or C9orf72 (described previously; Cruchaga et al., 2012).

Sequencing
Samples were sequenced using either whole-genome sequencing
(WGS, 12%) or whole-exome sequencing (WES, 88%). Exome
libraries were prepared using Agilent’s SureSelect Human All
Exon kits V3 and V5 or Roche VCRome (Table 2). Both
WES and WGS samples were sequenced on a HiSeq2000 with
paired end reads, with a mean depth of coverage of 50× to
150× for WES and 30× for WGS. Alignment was conducted
against GRCh37.p13 genome reference. Variant calling was
performed separately for WES and WGS following GATK’s
3.6 Best Practices (https://software.broadinstitute.org/gatk/bestpractices/) and restricted to Agilent’s V5 kit plus a 100 bp of

ADSP Cohort
The Alzheimer’s Disease Sequencing Project (ADSP) is a
collaborative work of five independent groups across the
USA that aims to identify new genomic variants contributing
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Frontotemporal Dementia, or Parkinson disease (Fernández
et al., 2017). We restricted the selection of families to those with
at least one case and one control in the family, and we excluded
any participants that were initially clinically diagnosed with AD
but had a different diagnosis after pathological examination.
Finally, our dataset consisted of 1,235 non-hispanic whites
(NHW), 824 cases and 411 controls, from 285 different families
(Table 1, Table S1). Of these 1,235 individuals, 1144 originated
from WUSM and 91 were from ADSP.

TABLE 2 | Number of samples for which whole genome sequencing (WGS) or
whole exome sequencing (WES) was performed, with detail of the exon library kits
employed in this study.
Exon library kit
WGS

WGS

WES

153

Agilent’s SureSelect Human All Exon kits V3

0

28

Agilent’s SureSelect Human All Exon kits V5

0

665

Roche VCRome

0

389

153

1,082

Total

Study Design and Analysis
The goal of this study was to test the performance and power
of different gene-based family-based methods currently available,
using a real dataset consisting of 1,235 non-hispanic white
individuals from 285 families densely affected with AD. We
created three different scenarios to test (Figure 2). First, using the
real phenotype and pedigree structure from 25 of the 285 families,
we generated a synthetic dataset with multiple variants and
families with perfect segregation. Second, we evaluated different
variant-combinations for the APOE gene. Third, we performed
genome-wide gene-based analysis of only nonsynonymous SNPs
with a MAF <1%. For each one of these scenarios we evaluated
the performance of the different gene-based methods (collapsing,
variance-component, and transmission disequilibrium) from
the following family-based packages: SKAT (Wu et al., 2011),
FSKAT (Yan et al., 2015), GSKAT (Wang et al., 2013), RVGDT
(He et al., 2017), EPACTS (http://genome.sph.umich.edu/wiki/
EPACTS), FarVAT (Choi et al., 2014), PedGene (Schaid et al.,
2013), RareIBD (Sul et al., 2016). Some of these software offer
the option to run different gene-based algorithms; e.g., GSKAT,
EPACTS, FarVAT or PedGene can run collapsing and variancecomponent tests; therefore, we ran a total of 25 models (Table 3).
The details of each one of these scenarios are described next.

padding added to each capture target end. We used BCFTOOLS
(https://samtools.github.io/bcftools/bcftools.html) to decompose
multiallelic variants into biallelic prior to variant quality control.
Variant Quality Score Recalibration (VQSR) was performed
separately for WES and WGS, and for SNPs and INDELs.
Only those SNPs and indels that fell above the 99.9 confidence
threshold, as indicated by WQSR, were considered for analysis;
variants within low complexity regions were removed from both
WES and WGS and variants with a depth (DP) larger than
the average DP + 5 SD in the WGS dataset were removed.
At this point SNPs and indels from WES and WGS datasets
were merged into one file. Non-polymorphic variants and those
outside the expected ratio of allele balance for heterozygosity
calls (ABHet = 0.3–0.7) were removed. Additional hard filters
implemented included quality depth (QD ≥ 7 for indels and
QD ≥ 2 for SNPs), mapping quality (MQ ≥ 40), fisher strand
balance (FS ≥ 200 for indels and FS ≥ 60 for SNPs), Strand Odds
Ratio (SOR ≥ 10 for Indels and SOR ≥ 3 for SNPs), Inbreeding
Coefficient (IC ≥ −0.8 for indels) and Rank Sum Test for
relative positioning of reference vs. alternative alleles within reads
(RPRS ≥ −20 for Indels and RPRS ≥ −8 for SNPs) (Figure S1).
We used PLINK1.9 (https://www.cog-genomics.org/plink2/ibd)
to remove variants that were out of Hardy Weinberg equilibrium
(p < 1 × 10−6 ), with a genotype calling rate below 95%, with
differential missingness between cases vs. controls, WES vs.
WGS, or among different sequencing platforms (p < 1 × 10−6 ).
Samples with more than 10% of missing variants (four
samples) and whose genotype data indicated a sex discordant
from the clinical database (three samples) were removed from
the dataset. Individual and familial relatedness was confirmed
using identity-by-descent (IBD) calculations, an existing GWAS
dataset for these individuals, and the pedigree information.
Because many of the ADSP families were also recruited from the
NIA-LOAD repository there is a certain overlap (48 individuals)
between the WUSM and the ADSP familial cohorts; we kept
the duplicate that had better genotyping rate after QC. Principal
Component Analysis (PCA) was calculated to corroborate
ancestry and restrict our analysis to only samples from European
American origin. Functional impact and population frequencies
of variants were annotated with SnpEff (Cingolani et al., 2012).
For this analysis, only SNVs with a minor allele frequency (MAF)
below 1%, as registered in ExAC (Lek et al., 2016), were tested.
We excluded families carrying a known pathogenic
mutation in any of the Mendelian genes for Alzheimer disease,

Frontiers in Neuroscience | www.frontiersin.org

Simulated Data
We selected 25 representative families from our entire dataset
for which there were genotypic data for three to seven members
(Table S2). We used the existing family structure and phenotypes
of these families, and a simulated gene called “GENE-A”
containing five variants. We generated several scenarios in which
different numbers of families presented perfect segregation with
disease status for a variant in GENE-A (Table 4, Table S2). First,
we considered a scenario in which only the first five families
of the dataset were included in the analyses and each family
presented a different perfectly segregating variant of GENEA [scenario 5 family carriers (FC) and 0 non-carriers (FNC):
5FC×0FNC]. Second, we generated additional scenarios in which
we kept the same five families as carriers of segregating variants
in GENE-A, and added five (scenario 5FC×5FNC), ten (scenario
5FC×10FNC), 15 (scenario 5FC×15FNC), and 20 (scenario
5FC×20FNC) families that were not carriers of any variant in
GENE-A. Then, we considered four scenarios of 25 families in
which each new scenario added families who were carriers of
a segregating variant in GENE-A. We started with the scenario
5FC×20FNC, then we simulated 10 families who had carriers
and 15 families who were non-carriers (scenario 10FC×15FNC),
15 families with carriers and 10 families who were non-carriers

4
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FIGURE 2 | Schematic design of the analysis performed in this study.

TABLE 3 | Relationship of programs and models tested according to their main features and kinship matrix that they use.
Collapsing
Burden
EPACTS

Variance-component

CMC

VT

X

X

C-ALPHA

Combined

SKAT

Transmission-disequilibrium

SKATO

IBS

Ped

X
X

SKAT-v2

X
X

X

X

FSKAT
FarVat-Adj

BN

X

RVGDT
GSKAT

Kinship

X

X

FarVat-BLUP

X

X

X

Pedgne

X

X
X
X

X

RareIbd

X

evaluate their power to associate perfect segregating variants with
disease.

(scenario 15FC×10FNC), 20 families with carriers and five
families who were non-carriers (scenario 20FC×5FNC) and
concluded with a scenario in which all 25 families were carriers
of one out of the possible five segregating variants in GENE-A
(scenario 25FC×0FNC). We tested each of these scenarios with
all previously mentioned gene-based methods and software to

Frontiers in Neuroscience | www.frontiersin.org

X
X

X
X

X

Candidate Genes
APOE is the largest genetic risk factor for Alzheimer’s disease.
The allelic combination of two SNPs, rs429358 (APOE 4;

5
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allele frequency equal to or below 1% (MAF ≤ 1%), based on
the EXAC dataset (Lek et al., 2016), and with a predicted high
or moderate effect, according to SnpEff (Cingolani et al., 2012),
were included in the analysis. Quantile-Quantile (QQ) plots from
gene-based p-values were generated with the R package “ggplot2”
(Wickham, 2009). We also evaluated the correlations between
these methods using Pearson correlation (Pc) and Spearman
correlation (Sc) tests of the log of the p-values using R v3.4.0 (R
Core Team, 2017). Pc evaluates the linear relationship between
two continuous variables whereas Sc evaluates the monotonic
relationship between two continuous or ordinal variables.

TABLE 4 | Representation of the segregation pattern of the simulated gene.
GENE-A
SNP1

SNP2

SNP3

SNP4

SNP5

Fam1

1

0

0

0

0

Fam2

0

1

0

0

0

Fam3

0

0

1

0

0

Fam4

0

0

0

1

0

Fam5

0

0

0

0

1

Fam6

1

0

0

0

0

Fam7

0

1

0

0

0

Fam8

0

0

1

0

0

Software Tested

Fam9

0

0

0

1

0

Fam10

0

0

0

0

1

Fam11

1

0

0

0

0

An accompanying supporting file (Supplementary Material)
provides a summary of the code employed to run each of the
programs described below.

Fam12

0

1

0

0

0

Fam13

0

0

1

0

0

GSKAT

Fam14

0

0

0

1

0

Fam15

0

0

0

0

1

Fam16

1

0

0

0

0

Fam17

0

1

0

0

0

GSKAT (Wang et al., 2013) is among the first R packages
developed with the goal of extending burden and kernel-based
gene set association tests for population data to related samples
with binary phenotypes. To handle the correlated or clustered
structure in the family data, GSKAT fits a marginal model with
generalized estimated equations (GEE). The basic idea of GEE is
to replace the covariance matrix in a generalized linear mix model
(GLMM) with a working covariance matrix that reflects the
cluster dependencies. Accordingly, GSKAT blends the strengths
of kernel machine methods and generalized estimating equations
(GEE) to test for the associations between a phenotype and
multiple variants in a SNP set. We ran GSKAT correcting for sex
and first two PCs.

Fam18

0

0

1

0

0

Fam19

0

0

0

1

0

Fam20

0

0

0

0

1

Fam21

1

0

0

0

0

Fam22

0

1

0

0

0

Fam23

0

0

1

0

0

Fam24

0

0

0

1

0

Fam25

0

0

0

0

1

One (1) means that all cases within the family are carriers of the variant. Zero (0) means
that the variant is not present in that family.

SKAT
The sequence kernel association test SKAT (Wu et al., 2011)
is an R package initially designed for case-control analyses.
Later they incorporated the Efficient Mixed-Model Association
eXpedited (EMMAX) algorithm (Kang et al., 2010; Zhou and
Stephens, 2012) which allows for performing family-based
analyses. EMMAX simultaneously corrects for both population
stratification and relatedness in an association study by using
a linear mixed model with an empirically estimated relatedness
matrix to model the correlation between phenotypes of sample
subjects. The efficient application of the EMMAX algorithm
depends on appropriate estimates of the variance parameters.
Relatedness matrices can be calculated based on pedigree
structure or estimated from genotype data. For the latter
different methods have been proposed. Relatedness can be
estimated using those alleles that have descended from a single
ancestral allele, i.e., those that are Identical by Descent (IBD), or
using the Balding-Nichols (BN) method (Balding and Nichols,
1995) which explicitly models current day populations via their
divergence from an ancestral population specified by Wright’s
Fst statistic. We ran SKAT v1.2.1, in R v3.3.3, using the option
SKAT_Null_EMMAX correcting for sex and first two PCs and
we tested four different kinship matrices: pedigree, IBS, BN and
a BN-based kinship matrix (HR) that the EPACTS software
constructs (Table S3).

19:45411941:T:C), and rs7412 (APOE 2: 19:45412079:C:T),
determines one of the three major isoforms of APOE protein,
ε2, ε3, or ε4. The dosage of these isoforms determines a person’s
risk for AD, from having a protective effect in the cases of APOE
ε2/ε2 (OR 0.6) or ε2/ε3 (OR 0.6) to different degrees of increased
risk according to the number of copies of the ε4 allele (ε2/ε4,
OR 2.6; ε3/ε4, OR 3.2; ε4/ε4, OR 14.9) (Farrer et al., 1997). We
tested the power of all previously mentioned gene-based methods
and software to detect the association of APOE gene with disease
in our entire dataset (N = 1,235) under different conditions.
We first tested all polymorphic variants (nonsynonymous with
MAF < 1%) in the APOE gene, next we tested only those variants
considered to have a high or moderate effect on the protein
including rs429358 and rs7412, then we tested high and moderate
effect variants alone, and finally tested rs429358 and rs7412 alone.

Genome-Wide Analyses
We performed gene-based burden analyses on a genome-wide
level in our entire dataset (families n = 285; samples N =
1,235) to evaluate the power of each of the previously described
methods to detect novel genes significantly associated with
disease; only single nucleotide variants (SNVs) with a minor
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6

April 2018 | Volume 12 | Article 209

Fernández et al.

Gene-Based Family-Based Methods in Alzheimer Disease

statistic over a genomic region of interest, which is usually a gene
(He et al., 2017). We ran RVGDT correcting for sex and first two
PCs.

FSKAT
FSKAT (Yan et al., 2015), also an R package, is based on a
kernel machine regression and can be considered an extension
of the sequence kernel association tests (SKAT and famSKAT)
for application to family data with dichotomous traits. FSKAT
is based on a GLMM framework. Moreover, because it uses
all family samples, FSKAT claims to be more powerful than
SKAT which uses only unrelated individuals (founders) in
the family data. FSKAT constructs a kinship matrix based on
pedigree relationships using the R kinship library. We ran FSKAT
correcting for sex and first two PCs.

RareIBD
The developers claim RareIBD (Sul et al., 2016) to be a program
without restrictions on family size, type of trait, whether founders
are genotyped, or whether unaffected individuals are genotyped.
The method is inspired by non-parametric linkage analysis and
looks for rare variants with segregation patterns among affected
and unaffected individuals that are different from the predicted
distributions based on Mendelian inheritance and computes a
statistic measuring the difference.

EPACTS
Efficient and Parallelizable Association Container Toolbox
(EPACTS) is a stand-alone software that integrates several genebased statistical tests (CMC, VT, and SKAT) and adapts them to
work with complex families by using EMMAX (https://genome.
sph.umich.edu/wiki/EPACTS). EPACTS generates a kinship
matrix based on the BN algorithm and also annotates the
genotypic input file and offers filtering tools (frequency and
predicted effect of variants) for easier user-selection of variants
that go into gene-based analyses. Nonetheless, we used the same
set of variants as in the other tests to run our analysis with
EPACTS, correcting for sex and first two PCs.

RESULTS
Simulated Dataset
Results from the simulated dataset indicate that RVGDT,
rareIBD, and collapsing-based methods (Burden, CMC, and
CLP) provided more statistical power than the variancecomponent methods to detect associations of perfectly
segregating variants with disease status (Table 5).
In a hypothetical scenario of five families in which each family
presented perfect segregation with disease status for a different
variant within the same gene (5FC×0NFC), transmissiondisequilibrium based methods evaluated this association as
significant (even after multiple test correction; e.g., RVGDT p
= 0.004; p-value after multiple test correction 0.004 × 9 =
0.036). RVGDT reached a ceiling p-value of 1 × 10−4 ; at 10
families with carriers (FC) plus 15 families of non-carriers (FNC).
RVGDT was unable to produce a p < 9 × 10−4 , therefore it
is not possible to rank or determine the significance of genes
that reach this limit. Similarly, RareIBD reports the same pvalue for all simulated scenarios, which may be an artifact or a
flaw of the program. Collapsing-based methods (Burden, CMC
and CLP) started with significant p-values for the 5FC×0NFC
scenario, but as we added FNC in the analyses, the associations
became less significant. Then as we increased the number
of FC of segregating variants, the associations became more
significant. In our analyses, most of the variance-component
tests could not work with the scenarios containing only five
families carrying the segregating variant; most of the tests only
provided p-values once 25 families were included in the analyses
(5FC×20FNC). After that, as we increased the number of FC of
segregating variants, the p-values became smaller. SKAT required
15FC×10FNC to report nominally significant p-values, GSKAT
required 20FC×5FNC to report statistically significant p-values,
FarVAT-CALPHA did not generate significant p-values unless
we used the BLUP correction; FarVAT SKATO reported p-values
that were significant at 15FC×10FNC, and at 5FC×20FNC if we
used the BLUP correction. P-values from EPACTS-SKAT were
not statistically significant after multiple test correction. FSKAT
did not deal well with perfectly segregating scenarios; it did not
provide p-values for a scenario of only five families all carriers
of the segregating variant (5FC×0FNC–FSKAT p-value = NA),
and after five families carrying a segregating variant, the program
saturated giving no p-value.

FarVAT
The Family-based Rare Variant Association Test (FarVAT) (Choi
et al., 2014) provides a burden and a variance component
test (VT) for extended families and extends these approaches
to the SKAT-O statistic. FarVAT assumes that families are
ascertained based on the disease status if family members
and compares minor allele frequencies between affected and
unaffected individuals. FarVAT is implemented with C++ and
is computationally efficient. Additionally, if genotype frequencies
of affected and unaffected samples are compared to detect genetic
associations, it has been shown that the statistical efficiency can
be improved by modifying the phenotype; and so FarVAT uses
prevalence (Lange and Laird, 2002) or Best Linear Unbalanced
Predictor (BLUP) (Thornton and McPeek, 2007) as covariate to
modify the genotype.

PedGene
PedGene (Schaid et al., 2013) is an R package that extends burden
and kernel statistics to analyze binary traits in family data using
large-scale genomic data to calculate pedigree relationships. To
derive the kernel association statistic and the burden statistic for
data that includes related subjects, they take a retrospective view
of sampling with the genotypes considered random.

RVGDT
The Rare Variant Generalized Disequilibrium Test (RVGDT) (He
et al., 2017), implemented with Python, differs from the previous
methods presented. Instead of using a kernel method to evaluate
variants, it uses the generalized disequilibrium test (GDT) which
tests genotype differences in all discordant relative pairs to assess
associations within a family (Chen et al., 2009). The rare-variant
extension of GDT (RVGDT) aggregates a single-variant GDT
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BN algorithm seemed to have a similar performance (SKAT-BN λ
= 0.038, SKAT-HR λ = 0.039, Table 7) though their concordance
was lower than expected considering they are based on the
same algorithm [Pearson correlation (Pc) = 0.85; Spearman
correlation (Sc) = 1]. Although the PED matrix generates a more
restrictive correction than the IBS matrix (SKAT-PED λ = 0.36,
SKAT-IBS λ = 0.67, Table 7), these two tests have a similar
overall performance as the p-values for the different genes were
highly correlated (Pc = 0.97; Sc = 0.98), making the PED matrix
a good surrogate for the IBS matrix. Finally, there were clear
performance differences between the BN-type matrices (BN and
HR) and the IBS-type matrices (IBS and PED), exemplified by the
different top candidate genes (NR1D1 for BN-type matrices and
CHRD for IBS-type matrices) and by the correlation algorithms
(SAKT-IBS vs. SKAT-BN Pc = 0.8; Sc = 0.89). Overall, we
found that the IBS matrix provided the best balance between
covariance-correction and overcorrection in our dataset.

Overall, Transmission-disequilibrium tests and collapsing
tests were the models that identified the simulated segregating
variants as associated with the phenotype; the CMC model
provided by FarVAT-BLUP was the one providing most genomewide significant p-values, even in the 5FC×0FNC scenario.

Candidate Genes-APOE
We examined the performance of four gene-sets generated for
the APOE gene with the 22 family-based gene-based methods in
our entire familial cohort. Neither the entire set of polymorphic
variants (set “gene” in Table 6) nor the set including only rare
nonsynonymous variants (set “HM” in Table 6) confer risk for
these families. The association seems to be driven by the common
APOE ε2 and ε4 variants, since only when these were included,
either alone (set “ε2ε4” in Table 6) or in conjunction with the
rest of the rare nonsynonymous variants (set “HM-ε2ε4” in
Table 6) did most of the tests yield a significant p-value (after
multiple test correction). Only EPACTS-SKAT did not report
the APOE ε2 and ε4 variants as significantly associated, after
multiple test correction, within our dataset (Table 6). The most
significant association for APOE ε2 and ε4 variants was reported
by FarVAT-CMC test.

Collapsing Tests
The collapsing methods tested from four different software
(PedGene, FarVAT, EPACTS and GSKAT) were Burden, CMC,
and VT (Figure 3C). To compare the different tests we followed
a similar approach as above, ran the different software with the
same imputed file, and compared the λ.
In our analyses, the burden test by GSKAT presented the
most deflated values; though the lambda does not illustrate this
(GSKAT-Burden λ = 1.71, Table 7) because of the initial inflation
among the low or non-significant genes. EPACTS-CMC (λ =
0.85) and EPACTS-VT (λ = 0.95) provided values closer to the
expected, and although their QQ-plots appear to follow a similar
trend, their correlation is low (Pc = 0.54; Sc = 0.68) and they
reported different top genes. The Burden and CMC methods
by FarVAT and FarVAT-BLUP provided p-values closest to the
expected (FarVAT-Burden λ = 0.98; FarVAT-CMC λ = 0.99,
FarVAT-BLUP-Burden λ = 1.03; FarVAT-BLUP-CMC λ = 1.07).
The correlation for the gene p-values was higher between results
generated by the same method (FarVAT-BLUP-CMC vs. FarVATBLUP-Burden Pc = 0.99; Sc = 0.96; FarVAT-CMC vs. FarVATBurden Pc = 0.98; Sc = 0.97) than between results generated
using the same algorithm (FarVAT-BLUP-CMC vs. FarVAT-CMC
Pc = 0.88; Sc = 0.8; FarVAT-BLUP-Burden vs. FarVAT-Burden
Pc = 0.85; Sc = 0.77). PedGene in the burden model was the
software that provided the most significant p-values; however,
these were clearly inflated compared to the predicted p-values
(Pedgene-Burden λ = 2.99, Table 7) and the results were not
correlated with any other Collapsing test (Pc and Sc values < 0.1).

Genome-Wide Analyses
Overall, we examined eight software and over 22 algorithms
for genome-wide association analyses in our extended family
dataset of 285 families and 1,235 non-hispanic white individuals.
We only included in the analyses nonsynonymous SNPs with
a MAF ≤ 1% and we corrected for sex and first two PCs. All
22 algorithms were run using the same input data. The results
for these 22 algorithms are described, grouped per category,
in the following sections. First, we compare the correction
effect provided by four kinship matrices (Figure 3A). Second,
we compare the performance of nine variance-component
software and algorithms (Figure 3B). Third is the comparison
of eight collapsing software and algorithms. Fourth, we compare
two transmission-disequilibrium tests. We conclude the results
section by providing a summary of the pros and cons
encountered while running these methods. Overall, most of
the results from the gene-based methods tested seemed quite
deflated. Only PedGene, FarVAT and Rare-IBD seemed to
provide values closer to or above the expected under the null
hypothesis. The most efficient in terms of power and p-value
inflation appears to be FarVAT with BLUP correction.

Kinship Matrices
We tested the correction provided by four kinship matrices using
the SKAT method with EMMAX correction implemented in
the R package SKATv2. The four kinship matrices tested were
pedigree calculation (PED), Identity By State (IBS) estimation,
Balding-Nichols (BN) estimation, and the kinship generated
by EPACTS (HR) which is also based on the BN algorithm
(Figure 3A). Table S3 offers a comparison of these kinships for
FAM#1 and FAM#2 of our simulated dataset. For these analyses,
we ran the SKAT-EMMAX method in our entire dataset, genewide, and calculated a QQ plot and inflation factor (λ) to obtain a
general ideal of the behavior of each matrix. Matrices based on the
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Variance Component Tests
This subset included all the Variance component-based
methods available, CLP, CALPHA and SKAT, from six different
software: PedGene, FarVAT, FSKAT, EPACTS, SKAT, and
GSKAT (Figure 3C). GSKAT was the software that reported
more deflated values, though the lambda does not illustrate
this (GSKAT-SKAT λ = 1.681, Table 7) because of the initial
inflation among the low or non-significant genes. GSKAT
was followed by SKAT and EPACTS which showed similar
λ and performance-values for each gene (Pc = 0.8, Sc =
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Simulated scenarios: 5FC, five families carrier of variants within the hypothetical gene; 5FC×5FNC, five families carrier of variants within the hypothetical gene and five families non-carrier of variants within the hypothetical gene;
5FC×10FNC, five families carrier of variants within the hypothetical gene and 10 families non-carrier of variants within the hypothetical gene; 5FC×15FNC, five families carrier of variants within the hypothetical gene and 15 families
non-carrier of variants within the hypothetical gene; 5FC×20FNC, five families carrier of variants within the hypothetical gene and 20 families non-carrier of variants within the hypothetical gene; 10FC×15FNC, 10 families carrier of variants
within the hypothetical gene and 15 families non-carrier of variants within the hypothetical gene; 15FC×10FNC, 15 families carrier of variants within the hypothetical gene and 10 families non-carrier of variants within the hypothetical
gene; 20FC×5FNC, 20 families carrier of variants within the hypothetical gene and five families non-carrier of variants within the hypothetical gene; 25FC, 25 families carrier of variants within the hypothetical gene.
*we tested SKAT, CMC, and VT on EPACTS, but CMC and VT reported all NA values so data is not shown.
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FSKAT

GSKAT

SET

TABLE 5 | Gene-based p-values for the simulated dataset under different scenarios for the gene-based methods tested in the subset of 25 families.
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FIGURE 3 | Quantile-quantile (QQ) plots from different family-based gene-based methods for all nonsynonymous variants with a MAF <1% in our family-based
dataset. (A) Comparison of SKAT test using different kinship matrices: pedigree calculation (PED), Identity By Similarity (IBS) estimation, Balding-Nichols (BN)
estimation, and the kinship generated by EPACTS (HR). (C) Comparison of different collapsing tests: GSKAT, EPACTS, FarVAT, and PedGene. (B) Comparison of
different variance-component gene-based methods: GSKAT, FSKAT, SKAT, EPACTS, FarVAT, and PedGene. (D) Comparison of transmission disequilibrium tests:
RVGDT and RareIBD.

0.8, Figure 4). The CLP, CALPHA, and SKATO methods by
FarVAT and FarVAT-BLUP provided p-values closest to the
expected (FarVAT-CLP λ = 1.00; FarVAT-CALPHA λ = 1.15;
FarVAT-SKATO λ = 1.02, FarVAT-BLUP-CLP λ = 1.11; FarVATBLUP-CALPHA λ = 1.26; FarVAT-BLUP-SKATO λ = 1.10).
FarVAT-CALPHA, FarVAT-SKATO, FarVAT-BLUP-CALPHA
and FarVAT-BLUP-SKATO reported the same top candidate
gene (CHRD) (Table 7), though the overall p-value correlation
was lower than expected considering they are based on the same
algorithm (FarVAT-SKATO vs. FarVAT-BLUP-SKATO Pc = 0.6,
Sc = 0.7; FarVAT-CALPHA vs. FarVAT-BLUP-CALPHA Pc =
0.82 Sc = 0.82, Figure 4). On the other hand, despite the fact that
FarVAT-CLP and FarVAT-BLUP-CLP had higher correlation (Pc
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= 0.85, Sc = 0.77), these two tests reported different top genes
(FarVAT-CLP top gene is MAS1L, and FarVAT-BLIP-CLP top
gene is NLRP9). PedGene in the SKAT model was the software
that provided the most significant p-values, but these were clearly
inflated (Pedgene-SKAT λ = 3.53, Table 7) and its correlation
with other variance component tests was low to null (Pc and Sc
values < 0.2).

Transmission Disequilibrium Tests
We tested two transmission disequilibrium tests, RVGDT and
Rare-IBD, which were designed to account for large extended
families of arbitrary structure (Figure 3D). Of these two, RVGDT
was the test that more closely approached the expected under the
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null (λ = 0.99), whereas Rare-IBD provided slightly inflated pvalues (λ = 1.450, Table 7). The correlation between these two
methods was very low (Pearson correlation = 0.23, Spearman
correlation = 0.17). A common issue with both methods was that
we observed some stratification toward more significant p-values
which made it difficult to determine a top significant gene.

In the analysis, only nonsynonymous variants (only SNVs) with a MAF<0.01, and the APOE ε2 and ε4, were considered and we adjusted by sex and PCAs. Highlighted in bold, significant p-values after multiple test correction.
gene, set of 19 polymorphic variants within APOE gene, including APOE ε2 and ε4 variants; HM-ε2ε4, set of variants considered HIGH or MODERATE including APOE ε2 and ε4 variants; HM, set of variants considered HIGH or
MODERATE without APOE ε2 and ε4 variants; ε2ε4, APOE ε2 and ε4 variants alone. N, number of variants that went into analysis.
*We tested SKAT, CMC, and VT on EPACTS, but CMC and VT reported all NA values so data is not shown.
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TABLE 6 | Gene-based p-values for the APOE gene under different gene-set scenarios for the gene-based methods tested in the entire dataset (N = 1235, 285 families).
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Pros and Cons of the Different Gene-Based Methods
Among all the methods tested, EPACTS and FarVAT are the most
user-friendly, time-efficient and versatile software. EPACTS is an
all-in-one package that annotates the input file, generates the
kinship matrix and performs gene-based analysis under different
conditions (minor allele frequency and predicted functionality of
the variant) with only tag specification. In addition, the program
can be run on a genome-wide basis or at a smaller scale given
genes or regions specified by the user. FarVAT can generate the
kinship matrix by either using the pedigree relationships or using
the genetic relationship among individuals. It does not annotate
the input file and requires that the user provide their own set of
genes and variants per gene to analyze; it allows the user to choose
between BLUP or prevalence to estimate and incorporate random
effects on the phenotype. FarVAT has initial conditioning that
only takes founder-based MAF, so when a genetic variant only
has minor alleles in non-founders (offspring) these numbers will
not be counted. This is a big limitation with respect to the other
programs that take into account all variants regardless of their
presence in founders or not. Since we only had genetic data for
siblings for many of our families, so no genetic data for founders,
we ran FarVAT with the “–freq all” option so that all variants
would be included regardless if they were present in founders or
not.
FSKAT, GSKAT, and SKAT require some R knowledge from
the user, and are less flexible. For FSKAT and GSKAT the user
has to provide a genotype, a phenotype, and a gene-set file. For
SKAT the user has to additionally provide the kinship matrix.
Because these programs were designed to run on a per gene basis,
these take longer computational time to be run on a genomewide level than EPACTS or FarVAT, even if the user parallelizes
computation. PedGene is also an R package that requires a
genotype, a phenotype file with complete pedigree information
(to generate the kinship matrix), and a gene-set file. PedGene
provides phenotype adjustment by logistic regression on the trait
of interest, but it does not allow for extra covariates, which
prohibits correction by multiple PCs or other variables. RVGDT
is a Python based program, quite user-friendly since it is operated
with simple command-line but is limited in its options. Similar
to FSKAT, GSKAT, and SKAT, it is designed to be run on a pergene basis for which loops and parallelization have to be set up
for genome-wide testing. The same applies to RareIBD which
requires a genotype, a phenotype, and a Kinship coefficient file for
each gene that the user wants to test. For each gene the program
first computes statistics for each founder within each family and
then calculates the gene-based p-value. The first step of this
process can easily take between 3 and 5 min for families with
<100 individuals; hence, the overall time for one gene is directly
dependent on the number of families and the time required for
a genome-wide analysis is proportional to the number of genes
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FIGURE 4 | Correlation plots from different family-based gene-based methods for genes with a p ≤ 0.005. (A) Pearson correlation correlates genes according to their
p-values. (B) Spearman correlation correlates genes according to their rankings.

tested using the same algorithms makes us suspicious of the
validity of these results.
CHRD was the gene with the third most significant p-value.
CHRD had a p ≤ 5 × 10−7 in three different models (FarVATCALPHA, FarVAT-SKATO, and FarVAT-BLUP-CALPHA).
Additionally, as we lowered the considered p-value threshold, we
found that more tests identified CHRD as a potential candidate
gene associated with AD. When we lowered the threshold to
suggestive genome-wide p-value (p ≤ 5 × 10−4 ) we found
that seven different models identified CHRD as significantly
associated with AD. Following the same method we found that
CLCN2, MAS1L, and PTK2B had p ≤ 5 × 10−05 in at least three
tests, and if we lowered the threshold to ≤5 × 10−4 p-value, these
genes were identified as significant by at least three additional
tests.
Among genes with a p ≤ 5 × 10−04 ; CPAMD8 was identified
by at least nine gene-based methods (FarVAT, FarVAT-BLUP, and
PedGene). The exact p-value for CPAMD8 could not be estimated
by RVGDT as it reported a p-value of 9 × 10−04 , which is
the most significant p-value reported by this test. Therefore, we
cannot conclude that CPAMD8 presented a p-value ≤ 5 × 10−04
by RVGDT. CHRD, CLCN2, MAS1L, PTK2B, and CPAMD8,
NLRP9, and HDLBP were also potential novel candidate genes
for familial LOAD as they had p ≤ 5 × 10−04 using at least five or
more tests (Table 8).
Since these were identified by multiple gene-based methods,
we wanted to determine whether any of these seven candidate
genes are involved in known AD pathways. Common variants in
PTK2B have been associated with AD risk at a genome-wide level
(Lambert et al., 2013). Our results indicate there are additional

being tested. Although it is possible to parallelize the jobs using a
high-performance cluster (if available) this program is the slowest
of all tested.
One of the major drawbacks we found is that some of these
programs do not accept missing data (FSKAT or RareIBD) or
will not generate a p-value if the gene set contains only one
variant (GSKAT, PedGene or FarVAT). FSKAT does not accept
missing data, and although it calculated p-values for genes that
only have one informative SNP (one-SNP-gene), there were at
least 75 (3.26%) of 2,154 one-SNP-genes for which the returned
p-value was “2.” GSKAT did not provide p-values for more than
1,875 one-SNP-genes. PedGene also had trouble generating pvalues for 44 one-SNP-genes out of a total of 1,916 singletons.
FarVAT did not generate p-values for the one-SNP-genes using
the Burden and SKATO models but it did generate p-values using
the CMC and CLP models for the same 1,875 one-SNP-genes.

Candidate Genes for FASe Project
Our results indicate that transmission disequilibrium tests
identify genes that have a Mendelian behavior, whereas collapsing
and variance-component tests identify genes that confer risk for
disease. Therefore, we decided to combine and compare results
from all approaches to identify the genes with most consistent
results (Table 8).
PedGene provided the most significant p-values for NTN5
(Pedgene-Burden p = 5.80 × 10−8 ; PedGene-SKAT p = 1.26
× 10−8 ) and ANKRD42 (PedGene-Burden p = 3.62 × 10−7 ;
PedGene-SKAT p = 1.16 × 10−7 ). However, the inflated p-values
observed and low correlation with any of the other software
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require either large datasets (e.g., the ADSP Discovery Phase
which has over 10,000 sequenced individuals) or datasets
enriched for rare variants (such as families with history of AD).
In this study, we present the most comprehensive performance
analyses of multiple gene-based methods using 285 families with
AD. Some of the current methods available are underpowered
or too restrictive to detect genes significantly associated with
this disease (Figure 4). Results from our simulated data (Table 5)
show that only certain highly-restricted scenarios provide genewide significant p-values in family-based analyses; whereas
similar scenarios in a case-control study would result in genewide p-values. To circumvent this power issue, we relied
on the combination of multiple evidence toward the same
gene.
One key aspect to adapt gene-based analyses to a familybased context is to account for population stratification and
hidden relatedness that may appear due to the inherent nature
of family datasets. To take into account this issue, gene-based
algorithms must incorporate kinship matrices to model the
relationships among samples. Therefore, an appropriate estimate
of the kinship matrix is of utmost importance. In this work
we show how different relationship matrices influence results.
We tested the three most common types of kinship matrix,
pedigree reconstruction (PED), identity by state (IBS), and
Balding-Nichols (BN). We show that for a situation of complex
incomplete families, correction using PED or BN matrices will
lead to an overcorrection of the relationships decreasing the
power of these tests (Table 7, Figure 4A).
In order to choose the best gene-based algorithm for analysis,
it is important to take into account the nature (impact and
directionality) of the variants that are being included in the
test. Collapsing tests are powerful when a large proportion of
variants are causal and the effects are in the same direction.
Variance-component tests are supposed to be more powerful
than collapsing tests because they allow for admixture of risk
and protective variants within the region being tested (IonitaLaza et al., 2013). It is not practical to account for the nature
of the variants included in each gene-set, and the true disease
model is unknown and variable; hence, omnibus or combined
tests such as SKAT-O would be desirable for genome-wide
studies (Lee et al., 2012). However, most family-based methods
do not incorporate the SKAT-O algorithm, except FarVAT.
Therefore, the best approach to perform genome-wide rare
variant discovery is to combine different algorithms and look for
common signatures across the tests performed. Nonetheless, we
are aware that running all available tests is a time-consuming task
that requires additional expertise and resources. In our analyses
FarVAT, with the BLUP adjustment, provide the best results in
terms of significant p-values and minor inflation, for genomewide gene-based analysis; it is a fast software that provides results
from multiple tests at the same time. The R version of SKAT
or EPACTS would be alternatively valid choices, taking into
account that these overcorrect and the p-value threshold should
be lowered.
In this study, we identified CHRD as a candidate gene
with a genome-wide significant p-value (5 × 10−07 ) reported
by three tests, and another six genes that had a suggestive

TABLE 7 | Top results for all gene-based methods tested.
Software

TEST

Top gene

Top p-value

Lambda

PedGene

SKAT

KANSL1L

2.42 × 10−12

3.533

PedGene

Burden

TTN

1.04 × 10−8

2.997

GSKAT

Burden

PCSK6

3.04 × 10−3

1.704

GSKAT

SKAT

NR1D1

1.90 × 10−3

1.681

Rare-IBD

TDT

SNTB2

1.00 × 10−4

1.450

FarVAT-BLUP

CALPHA

CHRD

4.60 × 10−07

1.259

FarVAT

CALPHA

CHRD

2.09 × 10−07

1.152

FarVAT-BLUP

CLP

NLRP9

1.14 × 10−4

1.112

FarVAT-BLUP

SKATO

CHRD

7.37 × 10−7

1.101

FarVAT-BLUP

CMC

IGHV1-69

1.28 × 10−4

1.066

FarVAT-BLUP

Burden

NLRP9

1.14 × 10−4

1.031

FarVAT

SKATO

CHRD

3.54 × 10−7

1.016

FarVAT

CLP

MAS1L

1.25 × 10−5

1.000

RVGDT

TDT

RTN3

9.99 × 10−4

0.995

FarVAT

CMC

HSD3B1

4.40 × 10−5

0.993

FarVAT

Burden

MAS1L

1.25 × 10−5

0.985

EPACTS

VT

PPAN-P2RY11

1.20 × 10−4

0.954

FSKAT

SKAT

CHRD

2.00 × 10−5

0.938

EPACTS

CMC

BTN2A2

1.05 × 10−3

0.849

SKAT

IBS

CHRD

7.94 × 10−5

0.668

EPACTS

SKAT

CHRD

2.42 × 10−5

0.635

SKAT

PED

CHRD

2.47 × 10−4

0.360

SKAT

HR

NR1D1

2.06 × 10−2

0.039

SKAT

BN

NR1D1

2.21 × 10−2

0.038

Top gene, p-value and lambda for each test is given, ordered by lambda value.

low-frequency and rare nonsynonymous variants in PTK2B that
are associated with AD risk in late-onset families.
We used the GeneMANIA (http://pages.genemania.org/)
algorithm on the seven candidate genes (CHRD, MAS1L, PTK2B,
CPAMD8, NLRP9, CLCN2, and HDLBP) and known ADrelated genes (APP, PSEN1, PSEN2, APOE, TREM2, PLD3, and
ADAM10) which are involved in some pathways important in AD
(APP-metabolism and immune response). GeneMANIA looks
for relationships among a list of given genes by searching within
multiple publicly available biological datasets. These datasets
include protein-protein, protein-DNA and genetic interactions,
pathways, reactions, gene and protein expression data, protein
domains and phenotypic screening profiles. We found that our
candidate genes have genetic interactions and co-localization
with known AD genes. CHRD and PTK2B are involved in
“regulation of cell adhesion” like ADAM10; PTK2B is involved in
“regulation of neurogenesis” like APOE and “perinuclear region
of cytoplasm” like APP, PSEN1 and PSEN2. Finally, CLCN2
and PTK2B are connected through “regulation of ion transport”
(Figure 5).

DISCUSSION
The missing heritability in AD, and in many complex diseases,
may be found in very rare variants for which discovery will
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FIGURE 5 | Gene network for the seven candidate genes (CHRD, CLCN2, CPAMD8, HDLBP, MAS1L, NLRP9, and PTK2B) with multiple evidence of a p ≤ 5 ×
10−04 , anchored with known AD genes (APP, PSEN1, PSEN2, APOE, TREM2, ADAM10, and PLD3), as described by GeneMANIA.

genome-wide p < 5 × 10−04 in at least five, and up to nine, of
the different test performed: CLCN2, CPAMD8, HDLBP, MAS1L,
NLRP9, and PTK2B. Additionally, these genes seem to have direct
and indirect interactions (genetic interaction, co-localization or
shared function) with known AD genes (APP, PSEN1, PSEN2,
APOE, TREM2, PLD3, and ADAM10).
CHRD, chordin, is a highly-conserved developmental protein
which inhibits the ventralizing activity of bone morphogenetic
proteins, is active during gastrulation, expressed in fetal and adult
liver and cerebellum, and is associated with Cornelia de Lange
syndrome (Smith et al., 1999). CLCN2, chloride voltage-gated
channel 2, has several functions including the regulation of cell
volume: membrane potential stabilization, signal transduction
and transepithelial transport. It has been associated with different
epilepsy modes (Saint-Martin et al., 2009; Cukier et al., 2014)
and leukoencephalopathy (Gaitán-Peñas et al., 2017). CHRD and
CLCN2 show co-expression which could be due to their close
proximity, both belong to a gene cluster at 3q27. Interestingly,
CLCN2 shows co-expression with TREM2 which, other than
being an AD risk gene, is known to cause leukoencephalopathy
in PLOSL (polycystic lipomembranous osteodysplasia with
sclerosing leukoencephalopathy), also known as Nasu-Hakola
disease.

Frontiers in Neuroscience | www.frontiersin.org

PTK2B, Protein Tyrosine Kinase 2 Beta, was described as an
AD risk locus in the largest GWAS meta-analysis conducted to
date (Lambert et al., 2013), and later corroborated by others
(Beecham et al., 2014; Wang et al., 2015). The protein encoded
by PTK2B is a member of the focal adhesion kinase (FAK)
family that can be activated by changes in intracellular calcium
levels, which are disrupted in AD brains. Its activation regulates
neuronal activity such as mitogen-activated protein kinase
(MAPK) signaling (Rosenthal and Kamboh, 2014). PTK2B could
also be involved in hippocampal synaptic function (Lambert
et al., 2013). Although there is no co-expression or genetic
interaction between CLCN2 and PTK2B, both are involved in
regulation of ion transport. Additionally, PTK2B is involved in
regulation of lipidic metabolic processes like APOE, a cholesterolrelated gene. Although no association has yet been reported
between APOE and HDLBP, the High-Density Lipoprotein
Binding Protein, the latter plays a role in cell sterol metabolism,
protecting cells from over-accumulation of cholesterol, which has
been reported as risk factor for atherosclerotic vascular diseases.
CPAMD8, C3 and PZP Like, Alpha-2-Macroglobulin Domain
Containing 8, has been previously associated with neurological
conditions other than AD. Common variants in CPAMD8 were
found among top markers associated with multiple sclerosis
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0.428

Highlighted in bold the tests with significant p-value according to threshold category.
*PedGene results have not been included given the inflated results of this test and the low correlation with the other gene-based methods.

0.299
1.32 × 10−5

1.22 × 10−4
2.89 × 10−4

6.51 × 10−6
0.009

4.92 × 10−4

0.009

4.92 × 10−4

0.011

1.79 × 10−4
0.046

1.12 × 10−5
6.46 × 10−6

(Baranzini et al., 2009). Missense and frameshift variants
in CPAMD8 were identified in three families affected with
Anterior Segment Dysgenesis (Cheong et al., 2016). According to
the UKBiobank PheWeb (http://pheweb.sph.umich.edu:5000/),
CPAMD8 has a 2.9 × 10−9 p-value for its association with AD.
We did not find any shared pathway between CPAMD8 and
known AD genes in the GeneMANIA network, even though
it seems to have a genetic interaction with APP (Lin et al.,
2010). In our study CPAMD8 was identified as a candidate
gene (with p < 1 × 10−4 ) for AD by at least nine gene-based
methods from different software, and we found that several
variants within this gene had varying degrees of segregation in
more than twenty families. Variant p.(Ser1103Ala) segregates
with disease status in two families with two and three carriers
respectively, and is present in another two families. Variant
p.(His465Arg) segregates with disease status in five families with
two or three carriers per family and is present in another 11
families. Variant p.(Arg1380Cys) is private to a family with three
carriers, p.(Ala1492Pro) is private to a family with five carriers,
and p.(Val521Met) is private to a family with three carriers.
MAS1L, MAS1 Proto-Oncogene Like, is a G Protein-Coupled
Receptor. Members of this family of membrane proteins are
activated by a wide spectrum of ligands and modulate the activity
of different signaling pathways in a ligand-specific manner. Aly
et al. (2008) described polymorphisms in the region of the
UBD/MAS1L genes that are associated with type-1 diabetes.
The immune system and the integrity of the blood-brain
barrier are key factors for Alzheimer disease. NLRP9, NLR Family
Pyrin Domain Containing 9, has been involved in inflammation
response. Nyúl-Tóth et al. (2017) found NLRP9 expressed in
cerebral endothelial cells and, at much lower levels, in brain
pericytes; and another member of the NLP family (NLRP1) has
been associated with AD (Pontillo et al., 2012).
We have reviewed more than 22 algorithms from eight
different software available for gene-based analyses in complex
families. After a thorough examination of the performance of
these tests under different scenarios, we present a methodology
to identify genes associated with the studied phenotype. We have
applied this methodology to 285 European-American families
affected with late onset Alzheimer disease (LOAD) and we
identified six candidate genes with suggestive or genome-wide
significant p-values across different software and algorithms.
Based on the consistency of our results, we are confident that
some of these genes may play a role in AD pathology and
therefore are of interest to follow up in replication and functional
studies.
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TABLE 8 | Most frequent genes, within p-value threshold category, across the different gene-based family-based methods tested*.
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